21 August 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies, a novel class of antibodyderived therapeutic proteins, announced that the Alzheimer’s disease collaboration with Boehringer Ingelheim was proceeding well and therefore the research funding has been extended for another year.
In January 2007 Boehringer Ingelheim and Ablynx announced that they had entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies ® , a novel class of therapeutic proteins. The deal also included a joint research programme with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialization of any products resulting from the collaboration. As part of the collaboration, Ablynx received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales... [PDF] Ablynx's Press Release -
